vs
FIDELITY D & D BANCORP INC（FDBC）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
RECURSION PHARMACEUTICALS, INC.的季度营收约是FIDELITY D & D BANCORP INC的1.5倍（$35.5M vs $24.4M），FIDELITY D & D BANCORP INC净利率更高（32.5% vs -304.2%，领先336.8%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 15.0%），FIDELITY D & D BANCORP INC自由现金流更多（$24.8M vs $-47.3M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 11.8%）
Fidelity D & D Bancorp Inc是一家总部位于美国的地区性银行控股公司，主要在宾夕法尼亚州东北部开展业务，为个人消费者、小微企业及当地社区客户提供存款账户、消费及商业贷款、抵押贷款、财富管理等综合零售及商业银行服务。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
FDBC vs RXRX — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $24.4M | $35.5M |
| 净利润 | $7.9M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | 37.7% | -304.8% |
| 净利率 | 32.5% | -304.2% |
| 营收同比 | 15.0% | 681.7% |
| 净利润同比 | 36.1% | 39.6% |
| 每股收益（稀释后） | $1.29 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $24.4M | $35.5M | ||
| Q3 25 | $23.5M | $5.2M | ||
| Q2 25 | $23.3M | $19.2M | ||
| Q1 25 | $22.0M | $14.7M | ||
| Q4 24 | $21.2M | $4.5M | ||
| Q3 24 | $20.4M | $26.1M | ||
| Q2 24 | $19.7M | $14.4M | ||
| Q1 24 | $19.5M | $13.8M |
| Q4 25 | $7.9M | $-108.1M | ||
| Q3 25 | $7.3M | $-162.3M | ||
| Q2 25 | $6.9M | $-171.9M | ||
| Q1 25 | $6.0M | $-202.5M | ||
| Q4 24 | $5.8M | $-178.9M | ||
| Q3 24 | $5.0M | $-95.8M | ||
| Q2 24 | $4.9M | $-97.5M | ||
| Q1 24 | $5.1M | $-91.4M |
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | — | 19.1% |
| Q4 25 | 37.7% | -304.8% | ||
| Q3 25 | 36.5% | -3327.6% | ||
| Q2 25 | 35.5% | -916.8% | ||
| Q1 25 | 32.2% | -1297.9% | ||
| Q4 24 | 31.4% | -4042.4% | ||
| Q3 24 | 28.2% | -377.1% | ||
| Q2 24 | 28.9% | -697.4% | ||
| Q1 24 | 29.5% | -698.4% |
| Q4 25 | 32.5% | -304.2% | ||
| Q3 25 | 31.2% | -3135.3% | ||
| Q2 25 | 29.7% | -894.2% | ||
| Q1 25 | 27.2% | -1373.3% | ||
| Q4 24 | 27.5% | -3935.5% | ||
| Q3 24 | 24.3% | -367.5% | ||
| Q2 24 | 25.0% | -676.6% | ||
| Q1 24 | 25.9% | -662.4% |
| Q4 25 | $1.29 | $-0.17 | ||
| Q3 25 | $1.27 | $-0.36 | ||
| Q2 25 | $1.27 | $-0.41 | ||
| Q1 25 | $1.03 | $-0.50 | ||
| Q4 24 | $1.00 | $-0.56 | ||
| Q3 24 | $0.86 | $-0.34 | ||
| Q2 24 | $0.86 | $-0.40 | ||
| Q1 24 | $0.88 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $148.1M | $743.3M |
| 总债务越低越好 | — | $9.6M |
| 股东权益账面价值 | $238.9M | $1.1B |
| 总资产 | $2.7B | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
| Q4 25 | $148.1M | $743.3M | ||
| Q3 25 | $142.2M | $659.8M | ||
| Q2 25 | $165.5M | $525.1M | ||
| Q1 25 | $211.2M | $500.5M | ||
| Q4 24 | $83.4M | $594.4M | ||
| Q3 24 | $120.2M | $427.6M | ||
| Q2 24 | $78.1M | $474.3M | ||
| Q1 24 | $72.7M | $296.3M |
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | — | — |
| Q4 25 | $238.9M | $1.1B | ||
| Q3 25 | $229.2M | $1.0B | ||
| Q2 25 | $217.9M | $919.1M | ||
| Q1 25 | $211.7M | $933.9M | ||
| Q4 24 | $204.0M | $1.0B | ||
| Q3 24 | $207.3M | $524.6M | ||
| Q2 24 | $195.7M | $584.4M | ||
| Q1 24 | $191.6M | $401.2M |
| Q4 25 | $2.7B | $1.5B | ||
| Q3 25 | $2.7B | $1.4B | ||
| Q2 25 | $2.7B | $1.3B | ||
| Q1 25 | $2.7B | $1.3B | ||
| Q4 24 | $2.6B | $1.4B | ||
| Q3 24 | $2.6B | $726.5M | ||
| Q2 24 | $2.5B | $775.9M | ||
| Q1 24 | $2.5B | $557.8M |
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $42.4M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $24.8M | $-47.3M |
| 自由现金流率自由现金流/营收 | 101.7% | -133.1% |
| 资本支出强度资本支出/营收 | 71.9% | 3.5% |
| 现金转化率经营现金流/净利润 | 5.34× | — |
| 过去12个月自由现金流最近4个季度 | $45.4M | $-378.3M |
8季度趋势，按日历期对齐
| Q4 25 | $42.4M | $-46.1M | ||
| Q3 25 | $8.4M | $-117.4M | ||
| Q2 25 | $12.6M | $-76.4M | ||
| Q1 25 | $11.7M | $-132.0M | ||
| Q4 24 | $29.6M | $-115.4M | ||
| Q3 24 | $9.1M | $-59.2M | ||
| Q2 24 | $8.7M | $-82.2M | ||
| Q1 24 | $5.3M | $-102.3M |
| Q4 25 | $24.8M | $-47.3M | ||
| Q3 25 | $2.2M | $-117.6M | ||
| Q2 25 | $6.9M | $-79.6M | ||
| Q1 25 | $11.5M | $-133.8M | ||
| Q4 24 | $24.9M | $-116.7M | ||
| Q3 24 | $7.8M | $-63.8M | ||
| Q2 24 | $7.2M | $-83.4M | ||
| Q1 24 | $4.0M | $-109.0M |
| Q4 25 | 101.7% | -133.1% | ||
| Q3 25 | 9.3% | -2272.5% | ||
| Q2 25 | 29.6% | -413.9% | ||
| Q1 25 | 52.3% | -907.4% | ||
| Q4 24 | 117.3% | -2567.7% | ||
| Q3 24 | 38.1% | -244.6% | ||
| Q2 24 | 36.6% | -578.5% | ||
| Q1 24 | 20.7% | -789.9% |
| Q4 25 | 71.9% | 3.5% | ||
| Q3 25 | 26.5% | 4.7% | ||
| Q2 25 | 24.4% | 16.4% | ||
| Q1 25 | 0.8% | 12.4% | ||
| Q4 24 | 22.0% | 28.6% | ||
| Q3 24 | 6.3% | 17.5% | ||
| Q2 24 | 7.5% | 8.2% | ||
| Q1 24 | 6.7% | 48.2% |
| Q4 25 | 5.34× | — | ||
| Q3 25 | 1.15× | — | ||
| Q2 25 | 1.82× | — | ||
| Q1 25 | 1.95× | — | ||
| Q4 24 | 5.07× | — | ||
| Q3 24 | 1.83× | — | ||
| Q2 24 | 1.76× | — | ||
| Q1 24 | 1.05× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
